Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the Oppenheimer & Co. 22
Annual Healthcare Conference. Dr. Pykett will provide an update of the Company and its development programs followed by a question and answer period with institutional investors on December 13, 2011 at 10:50 AM EST in New York City.
Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at
. Following the conference, the webcast will be archived for approximately 30 days.
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Neoprobe is actively developing two radiopharmaceutical agent platforms – Lymphoseek
CR – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit